Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.

Related documents

• State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.#1016098
• American Association for Thoracic Surgery Quality Gateway: A surgeon case study of its application in adult cardiac surgery for quality assurance.#1016099
• Metabolic Reprogramming of Cancer Stem Cells: Targeting Lipid Flux and Mitochondrial Plasticity to Overcome Therapeutic Resistance.#1016100
• Symptom Bother Is Associated With Medical Care‐Seeking for LUTS in Japanese Women: A Survey of 1800 Women.#1016101